TY - JOUR T1 - Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. JF - Mol Cell Endocrinol Y1 - 2014 A1 - Bernardi, Stella A1 - Fabris, Bruno A1 - Thomas, Merlin A1 - Toffoli, Barbara A1 - Tikellis, Christos A1 - Candido, Riccardo A1 - Catena, Cristiana A1 - Mulatero, Paolo A1 - Barbone, Fabio A1 - Radillo, Oriano A1 - Zauli, Giorgio A1 - Secchiero, Paola KW - Adipose Tissue KW - Adult KW - Animals KW - Blood Glucose KW - Body Mass Index KW - C-Reactive Protein KW - Case-Control Studies KW - Cholesterol, HDL KW - Cholesterol, LDL KW - Diet, High-Fat KW - Female KW - Humans KW - Inflammation KW - Insulin KW - Insulin Resistance KW - Male KW - Metabolic Syndrome X KW - Mice KW - Mice, Inbred C57BL KW - Middle Aged KW - Obesity KW - Osteoprotegerin KW - Triglycerides AB -

BACKGROUND: Inflammation is believed to link obesity to insulin resistance, as in the setting of metabolic syndrome (MetS). Osteoprotegerin (OPG) is a soluble protein that seems to exert proatherogenic and prodiabetogenic effects. This study aims at determining OPG levels in MetS and whether OPG might contribute to MetS development and progression.

METHODOLOGY/PRINCIPAL FINDINGS: Circulating OPG was measured in 46 patients with MetS and 63 controls, and was found significantly elevated in those with MetS. In addition, circulating and tissue OPG was significantly increased in high-fat diet (HFD) fed C57BL6 mice, which is one of the animal models for the study of MetS. To evaluate the consequences of OPG elevation, we delivered this protein to C57BL6 mice, finding that it promoted systemic and adipose tissue proinflammatory changes in association with metabolic abnormalities.

CONCLUSIONS/SIGNIFICANCE: These data suggest that OPG may trigger adipose tissue proinflammatory changes in MetS/HFD-induced obesity.

VL - 394 IS - 1-2 U1 - http://www.ncbi.nlm.nih.gov/pubmed/24998520?dopt=Abstract ER -